Verona Pharma: Great Year For Share Price, But Competition Threatens Bull Thesis
Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.
Is Verona Pharma plc (VRNA) the Best Performing Growth Stock in 2025?
We recently published a list of 10 Best Performing Growth Stocks in 2025 In this article, we are going to take a look at ...
Zacks Investment Research on MSN11d
Beat the Market the Zacks Way: Verona, Visa, Starbucks in Focus
Last Friday, the three most widely followed benchmark indexes closed a mixed week. The Nasdaq Composite and the S&P 500 ...
Truist Financial Keeps Their Buy Rating on Verona Pharma (VRNA)
In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Verona Pharma (VRNA – Research Report). The company’s ...
Verona Pharma (NASDAQ:VRNA) Price Target Raised to $75.00
Verona Pharma (NASDAQ:VRNA – Free Report) had its price objective increased by HC Wainwright from $60.00 to $75.00 in a report issued on Friday,Benzinga reports. The firm currently has a buy rating on ...
Yahoo Finance11d
Beat the Market the Zacks Way: Verona, Visa, Starbucks in Focus
Given the prevailing market uncertainty, you may want to look at our feats to prepare better for your next action. Shares of Verona Pharma plc VRNA have gained 50.7% (versus the S&P 500’s 0.8% ...